Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
9.2.2021 16:00:00 EET | Business Wire | Press release
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005141/en/
The acquisition expands Quotient’s service portfolio and will enable the integration of drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics®. By cutting through silos and integrating a range of capabilities, outsourced development programs can be further simplified and accelerated, consistent with Quotient’s belief that molecules need to become cures, fast.
“I’d like to congratulate the Arcinova team on building an exciting business, and I am thrilled to be joining forces. Both businesses are similar in culture and aspire to help customers accelerate molecules from candidate selection through development and on to commercial launch,” said Mark Egerton, Ph.D., CEO of Quotient Sciences. “I’d also like to take this moment to thank our private equity partner, Permira, for supporting our ambitious growth plans.”
Professor Ian Shott, CBE, co-founder and executive chairman of Arcinova, said, “Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers.”
As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018. Mark Bryant, BGF, said, “It has been a privilege to support the expansion of Arcinova’s world-leading CDMO facility at such a critical part of its growth journey. We wish the team all the best as it moves to the next stage with Quotient Sciences.”
RBC Capital Markets acted as exclusive financial advisor to Quotient Sciences. PwC provided financial and tax due diligence services and Latham & Watkins provided legal counsel. BGF received legal counsel from Weightmans. KPMG served as corporate finance adviser for Arcinova, and Womble Bond Dickinson provided legal counsel.
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
About Arcinova
Arcinova is a multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life changing medicines. The company, with decades of experience, combines agility with flexibility to provide an innovative approach to the development and manufacture of pharmaceutical products. Arcinova’s ambition is to save our clients valuable time, enabling them to rapidly bring life-changing medicines to market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005141/en/
Contact information
Jane Byram
SCORR Marketing
+1-512-626-2758
jane@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Announces First-Quarter 2026 Results24.4.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2026 Dec. 31, 2025 Mar. 31, 2025 Sequential Year-on-year Revenue $8,721 $9,745 $8,490 -11% 3% Income before taxes - GAAP basis $956 $943 $1,063 1% -10% Income before taxes margin - GAAP basis 11.0% 9.7% 12.5% 129 bps -156 bps Net income attributable to SLB - GAAP basis $752 $824 $797 -9% -6% Diluted EPS - GAAP basis $0.50 $0.55 $0.58 -9% -14% Adjusted EBITDA* $1,773 $2,331 $2,020 -24% -12% Adjusted EBITDA margin* 20.3% 23.9% 23.8% -358 bps -346 bps Pretax segment operating income* $1,321 $1,807 $1,556 -27% -15% Pretax segment operating margin* 15.2% 18.5% 18.3% -340 bps -318 bps Net income attributable to SLB, excluding charges & credits* $
Gamma Waves Launches: Playing Tomorrow’s Game Today24.4.2026 12:15:00 EEST | Press release
Gamma Waves, a permanent capital investment company, with the ambition to build an innovative sport-focused platform, launches today. Based in Amsterdam, the company was founded by Andrea Agnelli, Rocco Benetton and Giorgio Chiellini, with the aim of creating new value across: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424892627/en/ Gamma Waves Partners launched today, here is the team, including founders, Andrea Agnelli, Rocco Benetton and Giorgio Chiellini, along with Chief Investment Officer, Kyang Yung Sport IPs (Intellectual Properties): assets in globally captivating sectors such as basketball, hockey, cricket, tennis, baseball, rugby, etc., offering unique reach and credibility; Sports Tech: high-quality sports technology products that often struggle to scale because, on their own, they lack sufficient incentives and distribution to break through alongside IPs. Gamma Waves aims to bridge this gap by building a
Sovereign AI for the World: Cohere and Aleph Alpha to Form Global AI Powerhouse as Nations and Enterprises Demand Control Over Their Technology24.4.2026 12:15:00 EEST | Press release
Cohere and Aleph Alpha, two trusted sovereign AI providers for governments and regulated industries, today announce their plan to join forces. This transatlantic alliance would combine Cohere’s global AI scale with Aleph Alpha’s strong research excellence and deep institutional relationships, forging a globally competitive AI champion backed by their Canadian and German ecosystems. The initiative reflects a shared vision: To provide the world with an independent, enterprise-grade sovereign alternative in an era of growing AI concentration and to ensure that organizations do not need to relinquish control over their own AI stack. The planned combined entity1 will function as a transatlantic AI powerhouse, anchored in Germany and Canada, empowering organizations to choose, deploy and govern AI according to local laws, cultural contexts, and institutional requirements. By pooling top-tier engineering talent and computational resources across two G7 nations, the partnership aims to signifi
Porsche Sells Bugatti Stake to BlueFive Capital24.4.2026 11:00:00 EEST | Press release
Porsche has agreed to sell its equity stake in Bugatti Rimac. Porsche and Rimac Group established Bugatti Rimac as a joint venture in 2021 to serve as home to the iconic Bugatti brand. In this joint venture, Porsche holds a minority stake of 45%, Rimac Group owns 55%. Porsche also holds a 20.6% stake in Rimac Group. As part of the transaction announced today, Porsche will fully divest its equity stakes in Bugatti Rimac and Rimac Group to a HOF Capital-led consortium. This includes BlueFive Capital as its largest investor, as well as a group of institutional investors across the US and EU. Following completion, Rimac Group is set to take control of Bugatti Rimac and form a strategic partnership with BlueFive Capital and HOF Capital to support its continued growth. Hazem Ben-Gacem, Founder and Chief Executive of BlueFive Capital: “Bugatti is a monument to automotive obsession, born from Ettore Bugatti’s pursuit of beauty and performance combined. BlueFive Capital approaches this opportun
‘Concrete in Life 2025/26’ Winners Announced – Spectacular Photographs From Around the World22.4.2026 11:00:00 EEST | Press release
Powerful and striking images from around the world have been chosen as the winners of the Concrete in Life 2025/26 global photography competition, showcasing the essential role concrete plays in daily life, infrastructure, cities, and design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422352135/en/ OVERALL WINNER: Pillars Across the Sea by Celbert Palaganas, Cebu City, Philippines Run by the Global Cement and Concrete Association (GCCA), the annual competition received more than 20,000 entries from professional and amateur photographers, as well as smartphone users, spanning every continent. The competition highlights how concrete supports modern life while also offering moments of beauty, creativity and human connection. Thomas Guillot, Chief Executive of the GCCA, said: “The spectacular images submitted this year show concrete’s positive impact on people’s lives all over the world - sometimes practical, sometimes al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom